Commerce Bank Cuts Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Commerce Bank lowered its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 2.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,530 shares of the specialty pharmaceutical company’s stock after selling 305 shares during the period. Commerce Bank’s holdings in Supernus Pharmaceuticals were worth $422,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC lifted its stake in Supernus Pharmaceuticals by 97.1% in the third quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock worth $25,000 after acquiring an additional 398 shares during the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter worth $47,000. Innealta Capital LLC acquired a new position in shares of Supernus Pharmaceuticals during the second quarter worth $51,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Supernus Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock valued at $61,000 after buying an additional 352 shares during the last quarter. Finally, nVerses Capital LLC acquired a new stake in Supernus Pharmaceuticals in the second quarter valued at $72,000.

Supernus Pharmaceuticals Stock Performance

Supernus Pharmaceuticals stock opened at $36.14 on Wednesday. The company has a market capitalization of $2.00 billion, a P/E ratio of 33.78 and a beta of 0.86. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $39.37. The stock has a 50-day simple moving average of $33.81 and a 200-day simple moving average of $31.14.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.25. The company had revenue of $175.70 million during the quarter, compared to analysts’ expectations of $157.35 million. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The firm’s revenue for the quarter was up 14.2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.29) earnings per share. As a group, analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current year.

Insider Buying and Selling

In other news, SVP Frank Mottola sold 15,000 shares of the firm’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.98, for a total value of $554,700.00. Following the completion of the sale, the senior vice president now owns 8,200 shares in the company, valued at approximately $303,236. This trade represents a 64.66 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Georges Gemayel sold 14,213 shares of the business’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $36.62, for a total transaction of $520,480.06. Following the transaction, the director now owns 13,315 shares in the company, valued at approximately $487,595.30. This trade represents a 51.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 154,213 shares of company stock worth $5,660,180 in the last 90 days. Company insiders own 9.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on SUPN. Cowen reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. StockNews.com raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, Piper Sandler restated a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.